Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
MSD Files Oral COVID-19 Drug in Japan
MSD said on December 3 that it has filed its COVID-19 treatment molnupiravir in Japan seeking special emergency approval. It marks the first regulatory submission made in the country for an oral coronavirus treatment. Currently, Japan’s special emergency approval pathway…
To read the full story
Related Article
- MSD Japan Boosts COVID-19 Pill Supply to 800,000 Courses by March
February 15, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
December 27, 2021
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…